TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04052698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wilate
Description: Produced from the plasma of human donors, Wilate is presented as a powder or solvent for intravenous injection containing normally 500 IU or 1000 IU human VWF and human FVIII per vial. The ratio between VWF ristocetin co-factor activity (VWF:RCo) and FVIII:C is 1:1. The product contains approximately 100 IU/ml human VWF when reconstituted with 5ml/10mL water for injection with 0.1% polysorbate 80.~The specific activity of Wilate is ≥67 IU VWF:RCo/mg protein. The injection or infusion rate should not exceed 2-3mL per minute.
Study: NCT03869190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: For the control, + EV, + Nira, + Tira, and + SG arms, + RO7122290, Atezolizumab will be administered intravenously (IV) at a fixed dose of 1200 mg every 3 weeks (Q3W) on Day 1 of each 21-day cycle.~For the Atezo + Hu5F9-G4 and + TCZ arms, Atezo will be administered IV at a fixed dose of 840 mg every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: For the control, + EV, + Nira, + Tira, and + SG arms, + RO7122290, Atezolizumab will be administered intravenously (IV) at a fixed dose of 1200 mg every 3 weeks (Q3W) on Day 1 of each 21-day cycle.~For the Atezo + Hu5F9-G4 and + TCZ arms, Atezo will be administered IV at a fixed dose of 840 mg every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: For the control, + EV, + Nira, + Tira, and + SG arms, + RO7122290, Atezolizumab will be administered intravenously (IV) at a fixed dose of 1200 mg every 3 weeks (Q3W) on Day 1 of each 21-day cycle.~For the Atezo + Hu5F9-G4 and + TCZ arms, Atezo will be administered IV at a fixed dose of 840 mg every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.
Study: NCT03404596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Nicotine patches and thorough education of the indications for the patch will be provided to all participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Brief counseling sessions, 10-15 minutes each.
Study: NCT03869190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: For the control, + EV, + Nira, + Tira, and + SG arms, + RO7122290, Atezolizumab will be administered intravenously (IV) at a fixed dose of 1200 mg every 3 weeks (Q3W) on Day 1 of each 21-day cycle.~For the Atezo + Hu5F9-G4 and + TCZ arms, Atezo will be administered IV at a fixed dose of 840 mg every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: For the control, + EV, + Nira, + Tira, and + SG arms, + RO7122290, Atezolizumab will be administered intravenously (IV) at a fixed dose of 1200 mg every 3 weeks (Q3W) on Day 1 of each 21-day cycle.~For the Atezo + Hu5F9-G4 and + TCZ arms, Atezo will be administered IV at a fixed dose of 840 mg every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.
Study: NCT03404596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone
Description: Ecological momentary assessment (EMA) assesses participants' moment-to-moment subjective experiences via self-report assessments on a smart phone. Participants will receive mindfulness strategies for 10 days pre- and post-quit via smart phone to aid in their cessation attempt. Text messages will be sent to provided study phones throughout the day. These messages will be short (1-3 minutes long) and will ask participants to do things like focus on the present moment, pay attention to their breathing, and be aware of their current thoughts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AutoSense
Description: Participants will be asked to wear equipment throughout the day that will measure their physiology and smoking behavior. AutoSense unobtrusively and objectively collects physiological and behavioral data (i.e., negative affect (NA), self-regulatory capacity (SRC), and smoking) via wearable chest and wrist sensors.
Study: NCT01078701

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GHB11L1
Description: GHB11L1 administration by liquid nasal spray at doses of 6.0 log10, 6.5 log10 and 7.0 log10 TCID50/volunteer

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SPGN buffer
Study: NCT03869190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: For the control, + EV, + Nira, + Tira, and + SG arms, + RO7122290, Atezolizumab will be administered intravenously (IV) at a fixed dose of 1200 mg every 3 weeks (Q3W) on Day 1 of each 21-day cycle.~For the Atezo + Hu5F9-G4 and + TCZ arms, Atezo will be administered IV at a fixed dose of 840 mg every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: For the control, + EV, + Nira, + Tira, and + SG arms, + RO7122290, Atezolizumab will be administered intravenously (IV) at a fixed dose of 1200 mg every 3 weeks (Q3W) on Day 1 of each 21-day cycle.~For the Atezo + Hu5F9-G4 and + TCZ arms, Atezo will be administered IV at a fixed dose of 840 mg every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.
Study: NCT00588250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EmbryoGlue
Description: G2 culture media from Vitrolife which contains hyaluronic acid
Study: NCT03869190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: For the control, + EV, + Nira, + Tira, and + SG arms, + RO7122290, Atezolizumab will be administered intravenously (IV) at a fixed dose of 1200 mg every 3 weeks (Q3W) on Day 1 of each 21-day cycle.~For the Atezo + Hu5F9-G4 and + TCZ arms, Atezo will be administered IV at a fixed dose of 840 mg every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Enfortumab vedotin will be administered at a dose of 1.25 mg/kg IV on Days 1 and 8 of each 21-day cycle.
Study: NCT01067807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Proellex
Description: 25 mg - given as one 25 mg capsule (blended with microcrystalline cellulose, new formulation) \[Blended\], single dose
Study: NCT03869190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Enfortumab vedotin will be administered at a dose of 1.25 mg/kg IV on Days 1 and 8 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered at a dose of 200 mg once daily (QD) by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab (Hu5F9-G4)
Description: Participants will receive an 1-mg/kg priming dose IV on Day 1 followed by three weekly IV doses of 30 mg/kg on Days 8, 15, and 22. During Cycle 2, participants will receive weekly IV doses of 30 mg/kg on Days 1, 8, 15, and 22. For all subsequent cycles, participants will receive 30 mg/kg on Days 1 and 15. Cycle = 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Sacituzumab Govitecan will be administered at a dose of 10 mg/kg by IV on Day 1 and 8 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Sacituzumab Govitecan will be administered at a dose of 10 mg/kg by IV on Day 1 and 8 of each 21-day cycle.
Study: NCT01067807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg Proellex
Description: 50 mg - given as two 25 mg capsules (blended with microcrystalline cellulose, new formulation) \[Blended\], single dose
Study: NCT03869190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered by IV infusion at a dose of 8 mg/kg every 4 weeks (Q4W) on Day 1 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin will be administered at a dose of 70mg/m\^2 by IV on Day 1 of each cycle for Cycles 1-3 pre-surgery.
Study: NCT03721185

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Dr.K. Treatment
Description: Overweight and obesity treatment response

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Dr.K. Treatment
Description: Overweight and obesity treatment response
Study: NCT03972358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: All participants will receive 200 mg mifepristone, to be taken orally on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: All participants will receive 800 mcg misoprostol, to be taken buccally 24 hours after mifepristone (day 2)
Study: NCT03869190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered at a dose of 70mg/m\^2 by IV on Day 1 of each cycle for Cycles 1-3 pre-surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered at a dose of 1000mg/m\^2 by IV on Days 1 and 8 of each cycle for Cycles 1-3 pre-surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered at a dose of 1000mg/m\^2 by IV on Days 1 and 8 of each cycle for Cycles 1-3 pre-surgery.
Study: NCT02480426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT-image guidance
Description: TIPS creation is performed under the guidance of 3D CT-image.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CO2 portograms guidance
Description: TIPS creation is performed under the guidance of two-dimensional (2D) CO2 portograms.
Study: NCT03420768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986263
Description: Administered by intravenous (IV) infusion
Study: NCT02288130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRHa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal
Study: NCT01183351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Description: Multidisciplinary Intervention for challenging behavior in patients with Dementia (MID) is developed in clinical practice in nursing homes as an answer to the need of a systematic and simple tool for the nursing home health workers to meet agitation. The model is based on the theoretical framework of cognitive behavioural therapy (CBT) where human behaviour is understood as always acting under the influence of biological, social and psychological factors. The systematic and structured approach of CBT to problem solving is central and is transformed in the model to meet the specific characteristics of challenging behaviour in dementia.
Study: NCT01771666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosulfan blue
Description: 3 to 5 mL~If fluorescence is not detected with this dose, then it will be increased by 50%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99technetium-sulfur colloid radiolabel
Study: NCT01281813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Participants will receive darunavir (per parent study) as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Participants will receive ritonavir (per parent study) as oral solution/suspension.
Study: NCT02302287

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketoacids diet
Description: Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketoacids diet
Description: Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free diet
Description: Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free diet
Description: Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;

Intervention type: OTHER
Group type: OTHER
Intervention: Free diet
Description: Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;
Study: NCT04768153

Intervention type: BIOLOGICAL
Intervention: Serology
Description: Serological diagnosis of COVID-19 in patients with cancer from a sample of cancer patients, at 3 and 6 months after implementation of confinement in France
Study: NCT00995787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Dose titration of oral suspension of AZD165 during 3 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 6 days
Study: NCT00970307

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2202083A vaccine
Description: Intramuscular, three doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10-valent pneumococcal vaccine (GSK 1024850A)
Description: Intramuscular, three doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 10-valent pneumococcal vaccine (GSK 1024850A)
Description: Intramuscular, three doses
Study: NCT00480922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low glycemic load diet
Description: Outpatient behavioral counseling
Study: NCT00970307

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa™
Description: Intramuscular, three doses
Study: NCT00480922

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low fat diet
Description: Outpatient behavioral counseling
Study: NCT01506752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil Hydrochloride
Description: improved orally disintegrating E2020 10 mg tablet without water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil Hydrochloride
Description: current orally disintegrating E2020 10 mg tablet without water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil Hydrochloride
Description: improved orally disintegrating E2020 10 mg tablet with water.
Study: NCT00970307

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa™
Description: Intramuscular, three doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menjugate®
Description: Intramuscular, two doses
Study: NCT00995787

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose titration of oral suspension of placebo during 3 days given twice daily. Subjects will thereafter be for another 6 days
Study: NCT03028701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol/Budesonide 12/400 mcg Discair
Description: Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®
Study: NCT01895192

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of sperm morphology (contrast microscopy).
Description: Sperm head vacuoles were analyzed on 100 spermatozoa that were randomly photographed and separately analyzed using digital imaging system software. Interactive Measurement module allows measurement of sperm head areas and vacuole areas by manually depicting their outline. The area and position of each vacuole were recorded. Relative vacuole area is the ratio of the area of all the vacuoles of a spermatozoon to the area of its head.
Study: NCT03497377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-NaF
Study: NCT03606577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Induction 6 cycles 20/36 mg/m² on days 1, 2, 8, 9, 15, 16 (20 mg/m² on D1 and 2 cycle 1 only) Consolidation 4 cycles Carfilzomib 20 or 36 mg/m² on days 1, 2, 8, 9, 15, 16 (20 mg/m² on D1 and 2 first cycle only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: induction: 6 cycles Daratumumab 8/16mg/kg IV on Days 1, 8, 15, 22 for the first two cycle 2 and on days 1 and 15 for cycles 3 to 6. (8mg/kg on D1 \& D2 cycle 1 only) Consolidation: daratumumab 4 cycles 16mg/kg IV Day 1, Day 15 Maintenance Daratumumab 16mg/kg IV once every 8 weeks for 2 years (or until documented disease progression)
Study: NCT01506752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil Hydrochloride
Description: current orally disintegrating E2020 10 mg tablet with water
Study: NCT00547599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 20 mg tadalafil tablet by mouth as needed, no more than once a day for 8 weeks.
Study: NCT04538885

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The pleiotropic factor derived from mesenchymal stem cells
Description: The pleiotropic factor derived from mesenchymal stem cells was smeared on the wound with a dosage of (2.5mg/2cm2), and then the wound was covered with a foam dressing; the dressing was changed every 3 days to reach clinical healing as the end of the trial.
Study: NCT03768830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise program includes breathing and upper and lower limbs exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise program includes breathing and upper and lower limbs exercise.
Study: NCT02497872

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biliary stone removal
Description: Biliary stones are removed from the common bile duct by means of a sphincterotomy performed by standardized endoscopic retrograde cholangiopancreatography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary stone removal
Description: Biliary stones are removed from the common bile duct by means of a sphincterotomy performed by standardized endoscopic retrograde cholangiopancreatography
Study: NCT02021448

Intervention type: OTHER
Group type: OTHER
Intervention: Annual visits among 3 years. During each visit different testings are performed in order to detect an obesity-hypoventilation syndrome (OHS)
Description: Polygraphy/Polysomnography,Blood sampling, EKG,Lung function testing,Arterial blood gases,Thoracic radiography,Six-minute walk test,Respiratory questionnaires
Study: NCT03237988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPI-444 Capsules
Description: 100mg Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPI-444 Capsules
Description: 100mg Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPI-444 Capsules
Description: 100mg Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPI-444 Tablets
Description: 100mg Tablets
Study: NCT04519671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: Direct injection of adult allogeneic bone marrow derived mesenchymal stem cell product, at a dose of 75 million cells into perianal fistula(s)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT03606577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: induction: 6 cycles Lenalidomide 25 mg/day from day 1 to day 21 Consolidation: 4 cycles 15 mg/day from Day 1 to Day 21 (first cycle ) 25 mg/day from Day 1 to Day 21 (in the following cycle) Maintenance therapy 10mg/day, Day 1 to 21, for 2 years (or until documented disease progression)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: induction 6 cycles 20 mg/day on days 1-2, 8-9, 15-16 and 22-23 Consolidation 4 cycles 40 mg/Day on Days 1, 8, 15 and 22
Study: NCT02694978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Study: NCT03237988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPI-444 Tablets
Description: 100mg Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPI-444 Tablets
Description: 100mg Tablets
Study: NCT01996904

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic repair
Description: If the subscapularis tendon was not sufficiently mobile, further anterior interval release between subscapularis and scapula was performed. LHB (long head of biceps tendon) was either treated with a biceps tenodesis or by tenotomy when there was tear or subluxation of it. The footprint area of the subscapularis tendon, which is trapezoidal in shape on the proximal part of the lesser tuberosity, was thoroughly cleaned of soft tissue and meticulous bone preparation was done prior to placement of anchor sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopic debridement
Description: Anterosuperior portal was made initially for debridement (capsulectomy and anterior bursectomy). A systematic release of the glenohumeral ligaments and the overlying subscapularis bursa was performed.The superior aspect of the tendon was freed from the surrounding structures (the coracohumeral and superior glenohumeral ligaments). The middle glenohumeral ligament was always released to identify the upper border of the subscapularis tendon.